HUTCHMED (China) (HCM) vs NewAmsterdam Pharma N.V. (NAMS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
HUTCHMED (China) (HCM) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, losing 16.6% versus a loss of 35.3%. Over five years, NAMS leads with a +117.2% price change compared with -57.7% for HCM. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.49 billion vs $2.38 billion), about 1.0 times the size, while HUTCHMED (China) is growing revenue faster (-13.0% vs -50.6%).
HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus -905.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | NAMS |
|---|---|---|
| Share price | $13.67 | $21.26 |
| Market cap | $2.38B | $2.49B |
| 1-day change | -4.27% | -3.93% |
| YTD return | +2.55% | -39.40% |
| 1-year return | -16.60% | -35.30% |
| 5-year return | -57.68% | +117.16% |
| P/E ratio (TTM) | 136.70 | — |
| Forward P/E | 52.74 | — |
| EPS (TTM) | $0.10 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | $22.50M |
| Revenue growth (YoY) | -12.96% | -50.61% |
| Net income (latest FY) | $456.91M | $-203.82M |
| Gross margin | 38.68% | — |
| Operating margin | -7.14% | -1002.90% |
| Net margin | 83.30% | -905.74% |
| 52-week high | $16.33 | $42.21 |
| 52-week low | $9.77 | $20.91 |
| Distance from 52-week high | -16.29% | -49.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +61.01% | +133.54% |
| Average volume | 68.02K | 1.36M |
| Shares outstanding | 173.81M | 116.90M |
| Employees | 1,790 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HCM has outperformed NAMS by 18.7 percentage points over the past year.
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
- HUTCHMED (China) grew revenue faster in its latest fiscal year (-12.96% vs -50.61%).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
HCM vs NAMS FAQ
Which is bigger, HUTCHMED (China) or NewAmsterdam Pharma N.V.?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.49B compared with $2.38B for HUTCHMED (China) (HCM).
Which stock has performed better over the past year, HCM or NAMS?
HCM returned -16.60% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and NewAmsterdam Pharma N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.